rapcabtagene autoleucel + ibrutinib

Rapcabtagene autoleucel + ibrutinib is an experimental combination therapy comprising a next-generation autologous CD19-directed CAR-T cell therapy (rapcabtagene autoleucel, also known as YTB323) and the small molecule Bruton tyrosine kinase inhibitor ibrutinib. Rapcabtagene autoleucel is engineered to preserve T-cell stemness, enabling enhanced CAR-T cell persistence and efficacy. It is rapidly manufactured (<2 days) and targets the CD19 antigen on B-cell malignancies. Ibrutinib inhibits Bruton tyrosine kinase, a key signaling protein in B cells. This combination is under investigation for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not achieved a complete response after at least 6 months of ibrutinib treatment alone. The rationale is that ibrutinib may improve the function and expansion of infused CAR-T cells, offering a potentially synergistic mechanism for B-cell malignancy treatment.[1][2][3][6][7]